PBAC's latest decision on Inactivated quadrivalent influenza vaccine: Recommended (2016). Considered for Prevention of seasonal influenza caused by influenza virus Types A and B in adults aged 18 years and over.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Adults aged 18 years and older who are eligible to receive NIP-funded influenza vaccine.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Surrogate
Pivotal trial size
10,470 patients
Key trials
CSLCT, Kieninger et al. 2013, Tinoco et al. 2014, Beran et al. 2013
Comparator
Fluarix® Tetra influenza vaccine
Economic model
Cost-minimisation
Eligible patients/year
200,000
ICER note
Cost-minimisation analysis; no ICER calculated by design.